REFRACTORY HODGKIN LYMPHOMA
Clinical trials for REFRACTORY HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo after transplant shows promise for tough hodgkin lymphoma
Disease control OngoingThis study tests whether two immunotherapy drugs, nivolumab and brentuximab vedotin, can help prevent Hodgkin lymphoma from coming back after a stem cell transplant. It includes 62 people with high-risk lymphoma that returned or didn't respond to earlier treatments. The goal is t…
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 06:09 UTC
-
New weekly combo shows promise for Hard-to-Treat lymphoma
Disease control OngoingThis study tests whether giving a targeted drug (brentuximab vedotin) weekly, with or without another immune-boosting drug (nivolumab), can shrink tumors in people with CD30+ lymphoma that has come back or stopped responding to standard treatment. About 28 adults with relapsed or…
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 26, 2026 06:05 UTC
-
New hope for tough hodgkin lymphoma: immune drugs tested alone and together
Disease control OngoingThis study tests two immune-boosting drugs, ipilimumab and nivolumab, in people with classic Hodgkin lymphoma that has returned or not responded to prior therapy. The goal is to see if these drugs can shrink tumors when given alone or together. The trial enrolled 13 adults with m…
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
Double immune attack shows promise for stubborn hodgkin lymphoma
Disease control OngoingThis study tests whether giving a PD-1 inhibitor drug after CAR-T cell therapy can help control Hodgkin lymphoma that has come back or not responded to other treatments. Ten adults with this type of lymphoma will receive the combination to see if it improves response rates. The g…
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: EARLY_PHASE1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New combo therapy shows promise for Tough-to-Treat blood cancers
Disease control OngoingThis early-phase trial is testing a combination of two drugs—selinexor and choline salicylate—in 22 adults with certain blood cancers (lymphoma, multiple myeloma, or histiocytic/dendritic cell tumors) that have come back or not responded to prior treatment. The main goal is to fi…
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 18, 2026 12:09 UTC
-
Promising combo for tough hodgkin lymphoma cases shows strong response
Disease control OngoingThis study tested a combination of the immunotherapy drug nivolumab and chemotherapy (ICE) in 78 people with Hodgkin lymphoma that returned or didn't respond to initial treatment. The goal was to see if this approach could shrink tumors enough to allow a stem cell transplant. The…
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 18, 2026 12:00 UTC